Crinetics Pharmaceuticals
Trade Crinetics Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CRNX
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly.
CRNX Key Statistics
Stock Snapshot
With a market cap of 5.53B, Crinetics Pharmaceuticals(CRNX) trades at $53.91. The stock has a price-to-earnings ratio of -11.74.
On 2026-01-09, Crinetics Pharmaceuticals(CRNX) stock moved within a range of $53.52 to $56.13. With shares now at $53.91, the stock is trading +0.7% above its intraday low and -3.9% below the session's peak.
Trading volume for Crinetics Pharmaceuticals(CRNX) stock has reached 995.32K, versus its average volume of 1.92M.
Over the past 52 weeks, Crinetics Pharmaceuticals(CRNX) stock has traded between a high of $57.99 and a low of $24.10.
Over the past 52 weeks, Crinetics Pharmaceuticals(CRNX) stock has traded between a high of $57.99 and a low of $24.10.
CRNX News
Advertisement What Crinetics Pharmaceuticals Stock’s Recent Move Might Mean for Investors Crinetics Pharmaceuticals (CRNX) has drawn attention after recent sh...
Claim 70% Off TipRanks Premium Crinetics Pharmaceuticals ( (CRNX) ) has shared an update. On January 6, 2026, Crinetics Pharmaceuticals entered into an underw...
Claim 70% Off TipRanks This Holiday Season The latest announcement is out from Crinetics Pharmaceuticals ( (CRNX) ). On January 5, 2026, Crinetics Pharmaceuti...
Analyst ratings
88%
of 16 ratingsMore CRNX News
Crinetics Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Cory Jubinville, PhD from LifeSci Capital mainta...
RBC Capital analyst Brian Abrahams notes that Neurocrine’s (NBIX) CAH competitor Crinetics (CRNX) reported new phase II data from an additional cohort that were...